ACEP News - June 2008 - (Page 11)

Keppra® injection: The 1st and only 2nd-generation injectable anticonvulsant In the bag… without all the baggage: ■ NO blood level monitoring required for Keppra ■ NO cardiac monitoring necessary ■ NO loading dose required1 ■ NO known clinically significant drug interactions ■ NO reported incidence of purple glove syndrome in clinical studies2,3 ■ NO special handling required for storage of vial ® The 1st and only 2nd-generation, broad-spectrum AED with tablets, oral solution, and an intravenous formulation Keppra tablets and oral solution are indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy, myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. Keppra injection is indicated as adjunctive therapy in the treatment of myoclonic seizures in JME and partial onset seizures in adults with epilepsy. Keppra injection is an alternative for adult patients when oral administration is temporarily not feasible. Keppra tablets and oral solution are associated with the occurrence of central nervous system adverse events including somnolence and fatigue, behavioral abnormalities, and coordination difficulties, as well as hematological abnormalities. In pediatric patients 4-16 years of age experiencing partial onset seizures, the most common adverse events associated with Keppra in combination with other AEDs were somnolence, accidental injury, hostility, nervousness and asthenia. In adults experiencing partial onset seizures, the most common adverse events associated with Keppra in combination with other AEDs were somnolence, asthenia, infection and dizziness. In patients 12 years of age and older experiencing myoclonic seizures with JME, the most common adverse events associated with Keppra in combination with other AEDs were somnolence, neck pain, and pharyngitis. In patients 6 years of age and older experiencing PGTC seizures with idiopathic generalized epilepsy, the most common adverse event associated with Keppra in combination with other AEDs was nasopharyngitis. The adverse events that result from Keppra injection use for myoclonic seizures in JME and partial onset seizures include all of those associated with Keppra tablets and oral solution. ® ® ® ® ® ® ® ® ® ® References: 1. Ferrendelli JA. Concerns with antiepileptic drug initiation: safety, tolerability, and efficacy. Epilepsia. 2001;42(suppl 4):28-30. 2. Ramael S, Daoust A, Otoul C, et al. Levetiracetam intravenous infusion: a randomized, placebocontrolled safety and pharmacokinetic study. Epilepsia. 2006;47:1128-1135. 3. Ramael S, De Smedt F, Toublanc N, et al. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clin Ther. 2006;28:734-744. Keppra, The Epilepsy Company, and the “K” logo are trademarks of UCB S.A. or its affiliates. www.Keppra.com © 2008, UCB, Inc., Smyrna, GA 30080 All rights reserved. Printed in U.S.A. K4163-0208 http://www.Keppra.com http://www.Keppra.com

Table of Contents Feed for the Digital Edition of ACEP News - June 2008

ACEP News - June 2008 Contents News - Time to Move Tricks of the Trade - Revealing Tips Focus On - Dengue Fever Practice Trends - EMTALA Results

ACEP News - June 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.